https://novapharmanews.com/eu/news/eu-pharma-package-exclusivity-timelines-what-innovators-can-do-now 2026-06-17T07:41:18.208Z NovaPharmaNews en 2026-06-17T04:37:32.376Z EU Pharma Package exclusivity timelines: what innovators can do now https://novapharmanews.com/uploads/articles/eu-pharma-package-exclusivity-timelines-what-innovators-can-do-now.webp EU Pharma Package exclusivity timelines: what innovators can do now https://novapharmanews.com/us/news/biotechs-coming-of-age-ai-capital-efficiency-china 2026-06-18T01:57:46.027Z NovaPharmaNews en 2026-06-17T04:21:05.361Z Biotech’s coming of age: AI, capital efficiency and China reshape the field https://novapharmanews.com/uploads/articles/biotechs-coming-of-age-ai-capital-efficiency-china.webp Biotech’s coming of age: AI, capital efficiency and China reshape the field https://novapharmanews.com/us/news/edgewise-therapeutics-edg-7500-phase-2-cirrus-hcm-test 2026-06-18T01:57:39.465Z NovaPharmaNews en 2026-06-16T22:28:18.759Z Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test EDG-7500, hypertrophic cardiomyopathy, obstructive HCM, cardiac diastolic dysfunction https://novapharmanews.com/uploads/articles/edgewise-therapeutics-edg-7500-phase-2-cirrus-hcm-test.webp Edgewise Therapeutics’ EDG-7500 clears key Phase 2 test https://novapharmanews.com/us/news/celiac-disease-new-era-therapeutic-innovation 2026-06-18T01:57:49.697Z NovaPharmaNews en 2026-06-16T20:34:45.158Z Celiac disease therapies enter a new era of innovation Celiac disease https://novapharmanews.com/uploads/articles/celiac-disease-new-era-therapeutic-innovation.webp Celiac disease therapies enter a new era of innovation https://novapharmanews.com/us/news/fda-approves-otc-rextovy-broadening-naloxone-access-opioid-overdose 2026-06-18T12:19:17.508Z NovaPharmaNews en 2026-06-16T20:34:25.463Z FDA approves OTC Rextovy, broadening naloxone access for opioid overdose naloxone, naloxone hydrochloride, Rextovy, opioid overdose https://novapharmanews.com/uploads/articles/fda-approves-otc-rextovy-broadening-naloxone-access-opioid-overdose.webp FDA approves OTC Rextovy, broadening naloxone access for opioid overdose https://novapharmanews.com/us/news/neumora-navacaprant-fails-phase-3-engene-cuts-50-percent-of-staff 2026-06-18T07:20:15.109Z NovaPharmaNews en 2026-06-16T18:41:55.159Z Neumora navacaprant fails Phase 3 as EnGene cuts 50% of staff navacaprant, depression https://novapharmanews.com/uploads/articles/neumora-navacaprant-fails-phase-3-engene-cuts-50-percent-of-staff.webp Neumora navacaprant fails Phase 3 as EnGene cuts 50% of staff